Gyre Therapeutics
GYRE
31 hedge funds and large institutions have $6.31M invested in Gyre Therapeutics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% less funds holding
Funds holding: 32 → 31 (-1)
13% less capital invested
Capital invested by funds: $7.26M → $6.31M (-$951K)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $12K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$54.6K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$20.5K |
| 3 |
Morgan Stanley
New York
|
+$5.29K |
| 4 |
Bank of New York Mellon
New York
|
+$4.43K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$4.09K |
Top Sellers
| 1 |
DCM
DG Capital Management
New York
|
-$167K |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$120K |
| 3 |
D.E. Shaw & Co
New York
|
-$67K |
| 4 |
SIM
Spark Investment Management
New York
|
-$32K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$14.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
26
BlackRock Advisors
Wilmington,
Delaware
| $1K | – | – | – |
|
|
PAM
27
Panagora Asset Management
Boston,
Massachusetts
| $1K | – | – | – |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $1K | +$682 | +4 | New |
|
|
ACA
29
Avoro Capital Advisors
New York
| – | -$120K | -636 | Closed |
|
|
30
D.E. Shaw & Co
New York
| – | -$67K | -356 | Closed |
|
|
SIM
31
Spark Investment Management
New York
| – | -$32K | -170 | Closed |
|
|
BIM
32
BlackRock Investment Management
Wilmington,
Delaware
| – | -$2K | -8 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$341 | +2 | New |
|
GYRE Hedge Fund Activity: Q2 2016 in Review
31 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2016, worth a combined $6.31M — down 13% from $7.26M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GYRE and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $54.6K. The largest seller was DG Capital Management, cutting an estimated $167K.
- 31 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2016, down from 32 in Q1 2016.
- Funds reported $6.31M of Gyre Therapeutics stock for Q2 2016, down 13% quarter-over-quarter.
- 4 funds opened new Gyre Therapeutics positions in Q2 2016 and 5 closed out, a net change of -1 holder.
- The largest Gyre Therapeutics buyer in Q2 2016 was Renaissance Technologies, an estimated $54.6K added.
- The largest Gyre Therapeutics seller in Q2 2016 was DG Capital Management, an estimated $167K sold.
Based on aggregated 13F filings for Q2 2016.